Floatz logo

[18F]MC225

Mild Cognitive Impairment

University Medical Center GroningenSmall moleculePhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

149 Active assets in the Mild Cognitive Impairment cohort.

Asset / SponsorPhaseRating
Ginkgo Biloba Extract
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4BBB
Nicotine
University of Southern California
Phase 2BBB
Rivastigmine
Singapore General Hospital
Phase 4BBB
Oxybutynin
University of Alberta
Phase 4BBB
Rivastigmine
VA Office of Research and Development
Phase 4BB

View all 50 →

Same molecule, other indications

[18F]MC225 is also rated in:

neurodegenerative diseaseDormant
CCC
Indicative ·
48 / 100
View asset →
Alzheimer diseaseDormant
CC
Indicative ·
41 / 100
View asset →
Parkinson diseaseDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →